For information on treatments and vaccines for COVID-19, including those under evaluation by the CHMP:
The CHMP meets once per month. Its evaluations of marketing authorisation applications submitted through the centralised procedure provide the basis for authorisation of medicines in Europe.
Monthly lists of medicines under evaluation by the CHMP are available dating back to 2012. They contain the international non-proprietary names (INN) and therapeutic areas of innovative medicines. The INN contains only the active moiety for generic medicines and biosimilar medicines, with no information on salt, ester or derivative. The lists are available in Excel format from February 2021 to support data sorting and filtering.
The CHMP's independent recommendations on medicine for human use are based on a comprehensive scientific evaluation of data. For information on how EMA evaluates medicines and the CHMP's role in the authorisation of medicines in the EU:
Applications for new human medicines under evaluation: November 2024
English (EN) (99.08 KB - XLSX)
Applications for new human medicines under evaluation: October 2024
English (EN) (99.35 KB - XLSX)
Applications for new human medicines under evaluation: September 2024
English (EN) (99.58 KB - XLSX)
Applications for new human medicines under evaluation: August 2024
English (EN) (99.21 KB - XLSX)
Applications for new human medicines under evaluation: July 2024
English (EN) (774.32 KB - XLSX)
Applications for new human medicines under evaluation: June 2024
English (EN) (99.28 KB - XLSX)
Applications for new human medicines under evaluation: May 2024
English (EN) (816.88 KB - XLSX)
Applications for new human medicines under evaluation: April 2024
English (EN) (99.53 KB - XLSX)
Applications for new human medicines under evaluation: March 2024
English (EN) (99.39 KB - XLSX)
Applications for new human medicines under evaluation: February 2024
English (EN) (99.49 KB - XLSX)
Applications for new human medicines under evaluation: January 2024
English (EN) (563.08 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: December 2023
English (EN) (99.08 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: November 2023
English (EN) (99.01 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: October 2023
English (EN) (99.06 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: September 2023
English (EN) (99.03 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: August 2023
English (EN) (99.85 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: July 2023
English (EN) (98.86 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: June 2023
English (EN) (98.76 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: May 2023
English (EN) (98.47 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: April 2023
English (EN) (98.65 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: March 2023
English (EN) (98.73 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: February 2023
English (EN) (99.09 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: January 2023
English (EN) (98.73 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: December 2022
English (EN) (98.77 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: November 2022
English (EN) (109.4 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: October 2022
English (EN) (110.58 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: September 2022
English (EN) (111 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: August 2022
English (EN) (98.16 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: July 2022
English (EN) (110.1 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: June 2022
English (EN) (98.61 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: May 2022
English (EN) (98.68 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: April 2022
English (EN) (98.89 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: March 2022
English (EN) (99.24 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: February 2022
English (EN) (100.15 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: January 2022
English (EN) (99.26 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: December 2021
English (EN) (99.69 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: November 2021
English (EN) (775.78 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: October 2021
English (EN) (99.12 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: September 2021
English (EN) (99.19 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: August 2021
English (EN) (98.77 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: July 2021
English (EN) (98.69 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: June 2021
English (EN) (98.72 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: May 2021
English (EN) (98.71 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: April 2021
English (EN) (98.27 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: March 2021
English (EN) (98.09 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: February 2021
English (EN) (97.28 KB - XLSX)
Applications for new human medicines under evaluation by the CHMP: January 2021
English (EN) (104.11 KB - PDF)